Wu Jiafa, Luo Dongping, Li Shengnan
School of Food and Bioengineering, Henan University of Science and Technology, Luoyang, People's Republic of China.
The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, People's Republic of China.
Breast Cancer (Dove Med Press). 2022 Aug 15;14:211-227. doi: 10.2147/BCTT.S363114. eCollection 2022.
Breast cancer stem cells (BCSCs) are associated with tumor initiation, invasion, metastasis and drug resistance. It is known that many proteins and signaling pathways are involved in the regulation of BCSCs, however, much more efforts are needed to understand BCSCs comprehensively. Tumor-infiltrating immune cells are important in cancer treatment efficacy and patient prognosis. We tried to identify potential suppressor of BCSCs and analyze its correlation with various immune cells infiltration by bioinformatic and experimental methods.
Expression level and methylation state of OVOL2 were analyzed by tools from bc-GenExMiner v4.8 and UALCAN databases. The Kaplan-Meier plotter was applied to evaluate the prognostic values of OVOL2. Gene expression datasets (GSE7515, GSE15192) were selected to analyze differentially expressed genes (DEGs) related to BCSCs. GO and KEGG pathway analyses of DEGs were conducted. MCODE app plugin of Cytoscape was used to screen modules in PPI network of downregulated DEGs. Correlation of OVOL2 expression with infiltrating immune cells was evaluated by TIMER 2.0. Experiments were conducted to verify whether OVOL2 could inhibit stemness traits of breast cancer cell MDA-MB-231.
The expression level of OVOL2 in basal/TNBC was significantly lower than that of other subtypes. Survival analyses indicated that high expression of OVOL2 was associated with favorable prognosis. GO and KEGG pathway analyses for upregulated and downregulated DEGs were conducted. The top three clusters of downregulated DEGs showed that tight junction and chemokines may play important roles in BCSCs. OVOL2 is one module of clusters. OVOL2 expression is correlated with various immune cells infiltration. Experiments showed that OVOL2 suppresses CD44/CD24 ratio and mammospheres formation of MDA-MB-231.
OVOL2 may play an important role in the regulation of breast cancer stemness and immune cell infiltration, and is likely to be a target for the treatment of breast cancer.
乳腺癌干细胞(BCSCs)与肿瘤的起始、侵袭、转移及耐药性相关。已知许多蛋白质和信号通路参与BCSCs的调控,然而,要全面了解BCSCs仍需付出更多努力。肿瘤浸润免疫细胞对癌症治疗疗效和患者预后至关重要。我们试图通过生物信息学和实验方法鉴定BCSCs的潜在抑制因子,并分析其与各种免疫细胞浸润的相关性。
利用bc-GenExMiner v4.8和UALCAN数据库中的工具分析OVOL2的表达水平和甲基化状态。应用Kaplan-Meier绘图仪评估OVOL2的预后价值。选择基因表达数据集(GSE7515、GSE15192)分析与BCSCs相关的差异表达基因(DEGs)。对DEGs进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路分析。使用Cytoscape的MCODE应用插件筛选下调DEGs的蛋白质-蛋白质相互作用(PPI)网络中的模块。通过TIMER 2.0评估OVOL2表达与浸润免疫细胞的相关性。进行实验以验证OVOL2是否能抑制乳腺癌细胞MDA-MB-231的干性特征。
OVOL2在基底样/三阴乳腺癌(TNBC)中的表达水平显著低于其他亚型。生存分析表明,OVOL2高表达与良好预后相关。对上调和下调的DEGs进行了GO和KEGG通路分析。下调DEGs的前三个聚类表明紧密连接和趋化因子可能在BCSCs中起重要作用。OVOL2是聚类中的一个模块。OVOL2表达与各种免疫细胞浸润相关。实验表明,OVOL2可抑制MDA-MB-231的CD44/CD24比值和乳腺球形成。
OVOL2可能在乳腺癌干性和免疫细胞浸润的调控中起重要作用,有望成为乳腺癌治疗的靶点。